Crescent Biopharma Cash Flow Statement (2013-2026) | CBIO

Cash Flow Statement Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter)
-14.27M-14.40M-17.33M-17.42M-14.65M-13.27M-8.52M-10.24M-10.36M-8.26M-9.20M-9.08M-10.74M-10.10M-2.63M-2.34M-21.79M-24.61M-90.40M-23.28M
Depreciation and Depletion (Quarter)
0.07M0.07M0.07M0.06M0.06M0.05M0.05M0.05M0.04M0.04M0.04M0.02M0.01M-0.01M0.05M0.06M
Share-based Compensation (Quarter)
1.61M1.56M1.59M1.32M1.08M0.96M0.91M0.90M0.87M0.86M0.89M0.91M0.04M1.21M0.07M0.41M4.75M4.11M
Gains from Sales and Divestitures (Quarter)
0.19M0.19M0.08M0.11M0.11M0.11M0.07M0.07M0.07M0.07M0.06M0.06M0.06M0.05M
Gains from Investment Securities (Quarter)
-0.00M0.02M0.44M1.35M0.58M0.58M2.58M0.00M2.63M-0.09M0.00M0.09M8.99M1.63M0.01M
Non-cash Items (Quarter)
0.00M0.01M3.95M4.94M0.03M0.03M4.51M4.45M4.93M1.04M4.83M4.20M1.06M1.18M8.83M0.43M
Cash from Operations (Quarter)
-8.90M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)
0.18M0.18M0.19M0.19M0.20M0.20M0.21M0.21M0.22M0.22M0.23M0.19M0.17M-0.15M0.10M0.10M
Amortization of Deferred Charges (Quarter)
0.18M0.18M0.19M
Depreciation & Amortization (CF) (Quarter)
0.07M0.07M0.07M0.06M0.06M0.05M0.05M0.05M0.04M0.04M0.04M0.02M0.01M-0.01M0.05M0.06M
Change in Working Capital
Change in Receivables (Quarter)
-18.00M
Change in Account Payables (Quarter)
-2.31M
Change in Accured Expenses (Quarter)
-3.46M
Other Working Capital Changes (Quarter)
-0.10M
Investing Activities
Capital Expenditures (Quarter)
0.15M
Cash from Investing Activities (Quarter)
-8.15M
Change in Intangibles (Quarter)
8.00M
Financing Activities
Other financing activities (Quarter)
1.49M
Cash from Financing Activities (Quarter)
-6.95M
Additional items
Change in Cash (Quarter)
-24.03M
Free Cash Flow (Quarter)
-9.05M
Net Cash Flow (Quarter)
-23.99M